Contrasting Galectin Therapeutics (NASDAQ:GALT) and Sandoz Group (OTCMKTS:SDZNY)

Sandoz Group (OTCMKTS:SDZNY) and Galectin Therapeutics (NASDAQ:GALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Sandoz Group and Galectin Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-164.69%

Earnings & Valuation

This table compares Sandoz Group and Galectin Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$11.09 billion	3.31	$914.00 million	N/A	N/A
Galectin Therapeutics	N/A	N/A	-$30.84 million	($0.41)	-6.27

Sandoz Group has higher revenue and earnings than Galectin Therapeutics.

Institutional & Insider Ownership

0.1% of Sandoz Group shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Sandoz Group has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sandoz Group and Galectin Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	1	0	3	3.50
Galectin Therapeutics	1	0	1	0	2.00

Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 328.02%. Given Galectin Therapeutics’ higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Sandoz Group.

Summary

Sandoz Group beats Galectin Therapeutics on 6 of the 10 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.